However, the importance of brain 18F-FDG PET in the diagnosis of neurodegenerative diseases, especially AD, is currently debated in light of the diagnostic performance of CSF biomarkers, the advent of amyloid and tau PET radiotracers and the recent development of plasma biomarkers [10, 11]. Here, MAPT is linked to neurodegenerative disease.